Sander Busker is a scientist with a robust background in biomedical research, currently employed at Cytiva since August 2022. Prior experience includes a position as a scientist at Pelago Bioscience AB from February 2021 to August 2022 and serving as a postdoctoral researcher at Karolinska Institutet from January 2014 to February 2021, where investigations focused on the effects of electrophilic compounds on Thioredoxin reductase function. Sander developed biochemical methods to assess mechanisms of action for STAT3 inhibitors during a PhD and conducted research on L-dopa effects in a rat model of Parkinson's disease during an MSc internship. Additional early research involved studying resistance mechanisms to tyrosine kinase inhibitors in GBM cell lines and the impact of sympathetic hepatic nerve denervation on VLDL secretion at the Netherlands Institute for Neuroscience. Sander holds a Master's Degree in Biomedical Sciences with a concentration in Neurobiology and a Bachelor's Degree in Psychobiology, both obtained from the University of Amsterdam.
This person is not in any teams
This person is not in any offices